Key result
Intranasal inoculation with human rhinovirus type 2 induced specific antibody responses that peaked at 5 weeks and persisted for at least 1 year, providing protection against reinfection.
Why the study?
Does inoculation with human rhinovirus type 2 induce a specific humoral immune response in volunteers?
Population
17 volunteers inoculated with human rhinovirus type 2 (HRV-2)
Design
Cohort
Follow-up
1 year
Authors
Loading...
Supports year-long humoral protection post-HRV-2 exposure; hypothesis-generating and should not yet change practice.
Does inoculation with human rhinovirus type 2 induce a specific humoral immune response in volunteers?
HRV-2 infection induces a specific humoral immune response that peaks at 5 weeks and provides protection against reinfection for at least 1 year.
Barclay et al. (1989) studied Rhinovirus infection (n=21). Human rhinovirus type 2 (HRV-2) vs. Saline was evaluated on HRV-2-specific antibody response. Intranasal inoculation with human rhinovirus type 2 induced specific antibody responses that peaked at 5 weeks and persisted for at least 1 year, providing protection against reinfection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: